(19)
(11) EP 2 023 902 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.11.2010 Bulletin 2010/47

(45) Mention of the grant of the patent:
08.09.2010 Bulletin 2010/36

(21) Application number: 07728658.1

(22) Date of filing: 30.04.2007
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
A61P 3/10(2006.01)
 A61K 9/32(2006.01)
(86) International application number:
PCT/EP2007/054204
(87) International publication number:
WO 2007/128724 (15.11.2007 Gazette 2007/46)

(54)

DPP IV INHIBITOR FORMULATIONS

DPP-IV-INHIBITOR-FORMULIERUNGEN

FORMULATIONS DE L'INHIBITEUR DE DPP IV

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
BA HR RS

(30) Priority: 04.05.2006 EP 06009201

(43) Date of publication of application:
18.02.2009 Bulletin 2009/08

(60) Divisional application:
10175188.1
10175638.5

(73) Proprietors:
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    55216 Ingelheim (DE)
    Designated Contracting States:
    AT BE BG CH CY CZ DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR 
  • Boehringer Ingelheim Pharma GmbH & Co. KG
    55216 Ingelheim (DE)
    Designated Contracting States:
    DE 

(72) Inventors:
  • KOHLRAUSCH, Anja
    88400 BIBERACH (DE)
  • ROMER, Patrick
    88416 Ochsenhausen (DE)
  • SEIFFERT, Gerd
    88471 Laupheim (DE)

(74) Representative: Hammann, Heinz et al
Boehringer Ingelheim GmbH CD-Patents Binger Straße 173
55216 Ingelheim am Rhein
55216 Ingelheim am Rhein (DE)


(56) References cited: : 
EP-A- 1 537 880
WO-A-2007/017423
 WO-A-2004/018468
US-B1- 6 548 481
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).